The antitumor activity of spicamycin analogue SPMVIII against humanstomach, breast, lung, colon and esophageal cancers was compared to that of mitomycin C (MMC) in the human tumornude mice xenograft model. Comparative studies of SPMVIII given iv at 6mg/kg/day daily for 5 days and MMC given iv at 6.7mg/kg on day 1 revealed that the antitumor spectrum of SPMVIII showed a different pattern from that of MMC and that SPMVIII caused tumor mass reductions in more tumors than did MMC in colon cancers (4/12 versus 1/ll). In addition to this study, a comparative study of SPMVIII given iv at 12mg/kg/day 8 times at 3-or 4-day intervals and 5'-deoxy-5-fluorouridine (5'-DFUR) given po at 185 mg/kg/day 5 days per week for 4 weeks showed that SPMVIII had the highest effect on SC-9 human stomach cancer and COL-1humancolon cancer amongthe 3 compounds,resulting in a significant reduction of tumor mass. Although other pharmacological studies are in progress, these results suggest that SPMVIII might be a novel antitumor compoundeffective for humancancers including cancer of the digestive organs.
The antitumor activity of spicamycin analogue SPMVIII against humanstomach, breast, lung, colon and esophageal cancers was compared to that of mitomycin C (MMC) in the human tumornude mice xenograft model. Comparative studies of SPMVIII given iv at 6mg/kg/day daily for 5 days and MMC given iv at 6.7mg/kg on day 1 revealed that the antitumor spectrum of SPMVIII showed a different pattern from that of MMC and that SPMVIII caused tumor mass reductions in more tumors than did MMC in colon cancers (4/12 versus 1/ll). In addition to this study, a comparative study of SPMVIII given iv at 12mg/kg/day 8 times at 3-or 4-day intervals and 5'-deoxy-5-fluorouridine (5'-DFUR) given po at 185 mg/kg/day 5 days per week for 4 weeks showed that SPMVIII had the highest effect on SC-9 human stomach cancer and COL-1humancolon cancer amongthe 3 compounds,resulting in a significant reduction of tumor mass. Although other pharmacological studies are in progress, these results suggest that SPMVIII might be a novel antitumor compoundeffective for humancancers including cancer of the digestive organs.
Spicamycin is an antitumor antibiotic produced by Streptomyces alanosinicus 879-MT3 and was obtained as a mixture with a variety of fatty acid moieties1>2). In the previous study, we reported that spicamycin showed antitumor effect on several humantumor xenografts3). The antitumor activity of semi-synthetic spicamycin analogues against human gastric cancer SC-9 was also examined and SPMVIII with a dodecanoic acid residue ( Fig. 1 ) exhibited the highest antitumor activity among the tested spicamycin analogues. This activity was superior to that of mitomycin C (MMC) which is clinically used for many kinds of tumors3). Wehave thus pursued the antitumor activity of SPMVIII against other solid tumors with special emphasis on the spectrum of activity to determine its advantage over other drugs.
In this study we evaluated the antitumor activity of SPMVIII against nine stomach cancers, three breast cancers, three lung cancers, twelve colon cancers and one esophageal cancer by the humantumornude mice xenograft model which can predict the clinical efficiency of antitumor drugs4~8) with MMC or 5'-deoxy-5-fluorouridine (5'-DFUR) as controls. The antitumor activities of these compounds were evaluated by their efficacy at reducing tumor volume in addition to activity on inhibition of tumor growth.
Materials and Methods

Animals
Athymic female nude mice of 6-to 8-week-olds (BALB/c nu/nu Sic) were obtained from Japan SLC, Inc., Shizuoka, Japan. Throughout the experiments, the mice were maintained in a laminar flow cabinet under specific-pathogen-free conditions. They were fed with irradiated basal CE-2 diet (CLEA Japan, Inc., Tokyo, Japan) and given water ad libitum.
Tumors
A total of 28 cancers including nine human stomach cancers, three human breast cancers, three human lung cancers, twelve humancolon cancers and one humanesophageal cancer were used as shownin Table   1 (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) supplemented with 10% heat-inactivated fetal calf serum (Gibco Laboratories, Grand Island, NY, U.S.A.), 100units/ml of penicillin and 100units/ml of streptomycin (both from Meiji Seika Kaisha, Ltd., Tokyo, Japan). Other tumors were maintained by serial sc transplantations of about 2 x 2 x 2 mmcubic fragments in the right subaxillary region of the nude mice.
Antitumor Agents
MMCwas purchased from Kyowa Hakko Kogyo Co., Tokyo, Japan. 5'-DFUR was purchased from Nippon Roche Co., Ltd., Tokyo, Japan. SPMVIII semi-synthesized in our laboratory3) was dissolved in DMSOand an equal volume of Cremophor EL (Sigma Chemical Co., St. Louis, Mo., U.S.A.) was added. A 0.85% NaCl solution was added to make the final concentrations ofDMSOand Cremophor EL 1 % each. were randomly allocated to several experimental groups each consisting of five animals and chemotherapy wasstarted.
SPM VIII was injected iv daily for five days at the dosage level of 6mg/kg/day, and MMCwas injected iv only on day 1 at 6.7mg/kg in the comparative experiment of SPMVIII and MMC9). In the comparative experiment of SPM VIII and 5 -DFUR, SPM VIII was injected iv at 12mg/kg/day 8 times at 3-or 4-day intervals and 5'-DFUR was given at 185mg/kg/day by the po route daily for 5 days a week for 4 weeks11}.
Measurementof TumorSize
The tumor size was measured and calculated as described in a previous report3). Fromthe start of the injections, the tumor volume (V) was calculated once or twice a week for 3 weeks in the comparative experiment with SPMVIII and MMC, or for 6 weeks in the comparative experiment with SPMVIII and 5'-DFUR. The tumor growth inhibition rate (TGIR) was determined as TGIR=(1 -T/C) x 100, where T is the mean of relative tumor volumein the treated mice and C is the mean of relative tumor volume in the control mice.
Evaluation
The antitumor activity was evaluated from two perspectives. An "Effective" rating in the TGIRwas based on the maximumTGIR (%) of 50%or more showing statistical significance as determined by the Mann-Whitney U-test O < 0.05, one sided) without any mouse death. An "Effective" rating in the ability to reduce the tumor mass (expressed in Tables 2 and 3 as "Remission") was based on the minimal relative tumor volumeof less than 1 without any mouse death.
The response rate in the evaluation by TGIRwas calculated as the numberof tumors evaluated as Prior to the comparison study with MMC, we examined the optimal schedule for chemotherapy with SPMVIII. The result indicated that daily injection for 5 days was one of the most effective schedules for SPMVIII (data not shown), and the maximum tolerated dose (MTD) on this schedule was 6mg/kg/day. On the other hand, another optimal schedule was examined for the comparison study with 5'-DFURto adapt the span of chemotherapy to that of 5'-DFUR. As a result SPMVIII was injected twice a week for 4 weeks at an MTDof 12mg/kg/day. MMCwas injected by the optimal schedule described in the reference9) and 5'-DFUR was injected according to the schedule reported by Fujita et al.ll\ In both schedules, vehicle of SPMVIII did not show any effect on the tumor growth or any toxicity.
The effects of SPMVIII and MMC on humantumor xenografts are listed in Table 2 . The antitumor activity of SPM VIII against SC-9, COL-1, COL-5, COL-8, LS-174T and EH-10 was superior to that of MMC.On the other hand, MMChad higher antitumor activity against SC-6, St-40, MX-1, LX-1, Lu-99, Co-3, LS-180 and WiDr than that of SPMVIII. Other than these tumors, SC-2, St-15, NS-8, MC-2, COLO205 were evaluated as sensitive to SPM VIII by TGIR and/or remission. SC-7, St-4, 4-1ST, MC-8, Lu-24, CH-5, LoVo, HT-29 and DLD-1 did not respond to SPM VIII and/or MMC.The response rates Tumorcells or fragments were implanted sc into nude mice. Whenthe tumor volume reached 100~300mm3, 6mg/kg/day of SPMVIII was given iv daily for 5 days or 6.7mg/kg of MMCwas given iv on day 1. From the start of drug injection, the tumor volume was measured once or twice a week for several weeks. a Maximum TGIR through the experimental period; */?<0.05 compare to control, **/?<0.01. b +, Minimummean relative tumor volume in the experimental period was less than 1; -, 1 or more. of all human tumor xenografts to SPMVIII were approximately equal to those of MMC(52% versus 50% by TGIR and 39% versus 33% by remission, Table 3 ). The response rates of colon cancer to SPM VIII, however, were significantly higher than those of MMC(55% versus 33% by TGIR, 33% versus 9% by remission, Table 3 ). On the other hand, SPMVIII did not show advantage over MMCin breast, lung and esophageal cancers in this study. The results of the comparative study with SPMVIII and 5'-DFUR are listed in Table 4 . SPMVIII showed a strong effect on SC-9 and COL-1 resulting in a significant reduction of tumor masses. 5'-DFURhad no effect on these two tumors.
In the two comparative studies, SPM VIII showed the highest TGIR against SC-9 and COL-1 among the 3 drugs (Tables 2, 4) . The growth curves of COL-1 treated with SPMVIII or MMCare shown in Fig. 2 . SPMVIII significantly reduced the tumor volume from the beginning of chemotherapy, and the 
The response rates were calculated as a the number of tumors evaluated as effective according to the criteria for TGIR/number of evaluated tumors, bthe number of tumors showing tumor remission (indicated as " 4-" in Table 2 )/number of tumors evaluated. In both cases, the evaluation as effective was negated by one or more micedeaths. Tumorfragments were implanted sc into nude mice. When the tumor volume reached 100~300mm3, 12mg/kg/day of SPM VIII was given iv 8 times at 3-or 4-day intervals.
185mg/kg/day of 5'-DFUR was given po 20 times (5 times/week). From the start of drug injection, the relative tumor volume was measured once or twice a week for 6 weeks.
a MaximumTGIR through the experimental period; **/?<0.01 compared to control. b +, Minimummean relative tumor volume in the experimental period was less than 1; -, 1 or more. c -, All mice survived through the experimental period. d Underlined values were evaluated as "Effective" according to the criteria described in "Materials and Methods". relative tumor volume reached approximately 1/100 of the start volume. In contrast, MMC had no effect on reduction of the tumor volume. In accordance with the regression of tumor, the body weight of mice treated with SPM VIII rapidly increased (Fig. 3) .
Discussion
In this study we found that: 1) the antitumor spectrum of SPMVIII showed a different pattern from that of MMC, 2) the overall response rates of stomach, breast, lung, colon and esophageal cancers were approximately equal to those of MMC, 3) the response rates of colon cancers to SPMVIII evaluated by both TGIRand remission were higher than those of MMC and 4) SPMVIII had a strong effect especially on SC-9 and COL-1, being superior to those ofMMCand 5 -DFUR. SPMVIII showed wide therapeutic indices in both tumors (8 in SC-93) and 4 in COL-1, data not shown). Among these findings, the antitumor activity of SPMVIII against colon cancers is notable because the response rates of colon cancers to antitumor drugs are low in the humantumor xenograft model12) and also in clinical chemotherapy13). COL-1, which was most sensitive to SPMVIII among the tested cancers, is reported to be resistant to anticancer drugs including doxorubicin, cisplatin and fluorouracil14). Therefore, it is suggested that KRN5500is different from other drugs in both mode of action and antitumor spectrum. In the evaluation of antitumor effect, we emphasized the ability of tested compounds to reduce the tumor mass in addition to TGIRbecause the antitumor activities of drugs against solid tumors are usually Chemotherapy was started when the tumor (COL-1)
volume reached 100~300mm3 after about 3 weeks from the day of implantation. 6mg/kg/day of SPM VIII was given iv from days 1~5, or 6.7mg/kg of MMC was given iv on day , evaluated by the degree of tumor reduction in the clinical stage. The ability of SPMVIII to reduce the tumor mass demonstrated in this study is a notable
As structural similar compounds, septacidin and its analogues are reported. They have antitumor effects on murine adenocarcinoma CA755 and P388 murine leukemia15~17). But therapeutic effects of them on human tumors have not been reported and they have not been in clinical use yet.
Although the study of the mode of action of SPMVIII is still in progress, SPMVIII, which has a unique structure and a marked antitumor activity against humantumor xenografts, might be a novel antitumor compound effective for humancancers including cancer of the digestive organs.
